Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and radiotherapy in locally advanced cervical cancer
NCT05687851Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Dec 2022; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05687851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687851.